1732-55-4

Usage

Uses

Used in Pharmaceutical Industry:
Isothiazole, 4,5-dibromo-3-methylis used as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and reactivity. Its presence of bromine and methyl groups allows for further functionalization and modification, enabling the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
Isothiazole, 4,5-dibromo-3-methylserves as a building block in the creation of agrochemicals, such as pesticides and herbicides. Its halogenated nature and specific functional groups contribute to the effectiveness of these chemicals in controlling pests and weeds, thereby enhancing crop protection and yield.
Used in Dye Industry:
Isothiazole, 4,5-dibromo-3-methylis employed as a precursor in the production of dyes, particularly those with specific color properties and stability. Its unique structure allows for the development of dyes with improved performance characteristics, such as resistance to fading and better colorfastness.
Used in Materials Science:
Isothiazole, 4,5-dibromo-3-methylmay have potential applications in materials science, where its unique chemical properties can be utilized to develop new materials with specific properties, such as improved thermal stability, electrical conductivity, or mechanical strength.
Used in Organic Synthesis:
Isothiazole, 4,5-dibromo-3-methylis used as a versatile building block in organic synthesis, allowing for the creation of a wide range of organic compounds with diverse applications. Its reactivity and functional groups make it a valuable component in the synthesis of complex organic molecules for various industries.

Upstream product

• 71134-43-5 3-methyl-5-aminoisothiazole hydrochloride 
• 85508-99-2 4-bromo-3-methyl-isothiazol-5-amine 

Relevant academic research and scientific papers

Amide compound and application thereof as TGR5 agonist

Belonging to the technical field of medicine, the invention in particular relates to an amide TGR5 agonist compound shown as formula (I), its pharmaceutically acceptable salts, esters, stereoisomers, solvent compounds or prodrugs, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X, Y, Z, and ring A are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations, pharmaceutical compositions, and application of the compounds in preparation of drugs for treatment and/or prevention of TGR5 activity regulation related diseases. (formula (I)).

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula II.

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I), as follows: wherein R1, R2, R4, W, X, Y, and G, are defined herein.

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III); wherein R1c, R2C, R4C, Wc, Yc, Zc and Gc, are defined herein.

MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.